Although the data safety monitoring board will have access to the unblinded data when the futility analysis is performed, I am not expecting any data to be publicly released for the apabetalone vs. placebo group(i.e. no RRR number) in the news release regarding the futility analysis. I don't think even Resverlogix will be privy to this info.....just the DSMB. Like Led said, just a recommendation to continue, to halt, or to continue with modifications will come out of the news release....here's an example for anacetrapib from Nov 2015.

BearDownAZ